The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | The role of PET-CT in the diagnosis and prognosis of multiple myeloma
Noemi Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, describes the uses and benefits of PET-CT in patients with multiple myeloma and other monoclonal gammopathies. PET-CT can identify bone damage and be used as a part of the diagnostic workup when MRI is unavailable. PET-CT can additionally detect changes in the metabolic activity of cancer cells, which is used for treatment response assessment and for prognosis post-autologous transplantation. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Celgene: Honoraria, Speakers Bureau; Amgen, Celgene, Takeda and The Binding Site: Honoraria; Celgene, Janssen, Amgen and Takeda: Research Funding; Amgen, Celgene, Janssen and Takeda: Consultancy.
